IBER
Income statement / Annual
Last year (2021), Ibere Pharmaceuticals's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2021, Ibere Pharmaceuticals's net income was $1.56 M.
See Ibere Pharmaceuticals,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2021
|
| Period Ended |
12/31/2021 |
| Operating Revenue |
$0.00 |
| Cost of Revenue |
$1.00 M
|
| Gross Profit |
-$1.00 M
|
| Gross Profit Ratio |
0
|
| Research and Development Expenses |
$0.00
|
| General & Administrative Expenses |
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
| Selling, General & Administrative Expenses |
$0.00
|
| Other Expenses |
$1.00 M
|
| Operating Expenses |
$1.00 M
|
| Cost And Expenses |
$1.00 M
|
| Interest Income |
$17,116.00
|
| Interest Expense |
$0.00
|
| Depreciation & Amortization |
-$2.55 M
|
| EBITDA |
-$3.55 M |
| EBITDA Ratio |
0
|
| Operating Income Ratio |
0
|
| Total Other Income/Expenses Net |
$2.57 M
|
| Income Before Tax |
$1.56 M
|
| Income Before Tax Ratio |
0
|
| Income Tax Expense |
-$17,116.00
|
| Net Income |
$1.56 M
|
| Net Income Ratio |
0
|
| EPS |
0.34 |
| EPS Diluted |
0.34 |
| Weighted Average Shares Out |
$14.87 M
|
| Weighted Average Shares Out Diluted |
$14.87 M
|
| Link |
|
